In DMD, early-phase trials demonstrated improved dystrophin levels and delayed disease progression, leading to conditional approval by the European Medicines Agency (EMA) in 2014 for ambulatory pediatric patients ≥ 2 years [72]. Here, DMD is linked to Duchenne muscular dystrophy.